Nyxoah SA.
ISIN: BE0974358906
WKN: A2QCWK
08 October 2024 02:00PM

EQS-News: Nyxoah Raises $27 Million through its At-the-Market Offering

Nyxoah SA. · ISIN: BE0974358906 · EQS - Company News
Country: Belgium · Primary market: Belgium · EQS NID: 2004407

EQS-News: Nyxoah SA. / Key word(s): Financing
Nyxoah Raises $27 Million through its At-the-Market Offering

08.10.2024 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Nyxoah Raises $27 Million through its At-the-Market Offering 

Investment by a new U.S.-based healthcare investor, strengthening the balance sheet and reinforcing U.S. focus

Mont-Saint-Guibert, Belgium – October 8, 2024 – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company has sold 3.0 million shares raising $27.0 million in gross proceeds pursuant to the Company’s $50 million at-the-market ("ATM") offering at a price per share equal to the market price on the Nasdaq Global Market at the time of sale. The shares were sold, based on interest received, to a single U.S.-based healthcare investor. Cantor Fitzgerald & Co. is acting as the sales agent for the ATM offering.

The ordinary shares described above were sold by the Company pursuant to the Company’s shelf registration statement on Form F-3 (File No. 333-268955), filed with the Securities and Exchange Commission (“SEC”) on December 22, 2022, which became effective on January 6, 2023, and which included a prospectus supplement and accompanying prospectus related to the ATM offering. Copies of the prospectus supplement and accompanying prospectus related to the ATM offering may be obtained from Cantor Fitzgerald & Co., attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022; email: prospectus@cantor.com. Electronic copies of the prospectus are also available on the SEC's website at http://www.sec.gov.

Olivier Taelman, Chief Executive Officer of Nyxoah, commented: “After relocating to the United States with my family this past summer, this investment reinforces our United States focus, builds on our compelling DREAM pivotal study data presented at the International Surgical Sleep Society (ISSS) congress and strengthens our financial position, providing additional opportunities as we are preparing for the launch of Genio® in the United States.”

About Nyxoah

Nyxoah is reinventing sleep for the billion people that suffer from obstructive sleep apnea (OSA). We are a medical technology company that develops breakthrough treatment alternatives for OSA through neuromodulation. Our first innovation is Genio®, a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable. Through our commitment to innovation and clinical evidence, we have shown best-in-class outcomes for reducing OSA burden.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

FORWARD-LOOKING STATEMENTS

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and reporting data from Nyxoah’s DREAM U.S. pivotal trial; receipt of FDA approval; entrance to the U.S. market; and the anticipated closing and use of the proceeds from the offering. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in the offering, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Contacts:

Nyxoah

Loïc Moreau, Chief Financial Officer
IR@nyxoah.com

For Media

In United States
FINN Partners – Glenn Silver
glenn.silver@finnpartners.com

In Belgium/France
Backstage Communication – Gunther De Backer
gunther@backstagecom.be

In International/Germany
MC Services – Anne Hennecke
nyxoah@mc-services.eu



08.10.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Nyxoah SA.
Rue Edouard Belin 12
1435 Mont-Saint-Guibert
Belgium
E-mail: info@nyxoah.com
Internet: www.nyxoah.com
ISIN: BE0974358906
WKN: A2QCWK
Listed: Regulated Unofficial Market in Dusseldorf, Frankfurt, Munich, Stuttgart
EQS News ID: 2004407

 
End of News EQS News Service

2004407  08.10.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2004407&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 0,00 0,00 0,07 0,85 3,08 4,35 5,20
EBITDA1,2 -8,36 -7,29 -10,60 -25,46 -31,38 -43,70 -51,00
EBITDA-Margin3 0,00 0,00 -15.142,86 -2.995,29 -1.018,83 -1.004,60 -980,77
EBIT1,4 -8,45 -7,72 -11,22 -26,24 -32,50 -45,10 -55,00
EBIT-Margin5 0,00 0,00 -16.028,57 -3.087,06 -1.055,20 -1.036,78 -1.057,69
Net Profit (Loss)1 -9,08 -8,45 -12,25 -27,62 -31,23 -43,21 -60,00
Net-Margin6 0,00 0,00 -17.500,00 -3.249,41 -1.013,96 -993,33 -1.153,85
Cashflow1,7 -8,14 -5,97 -7,02 -25,34 -28,76 -44,78 -40,00
Earnings per share8 0,00 0,00 0,00 0,00 0,00 0,00 -1,75
Dividend per share8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: Ernst & Young

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Nyxoah
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
A2QCWK BE0974358906 SA 311,08 Mio € 09.09.2020 9F26MJ5H+99
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
0,00 24,44 0,00 0,00 2,97 -6,95 71,54
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,00 0,00 0,00 0,00%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
11.06.2025 13.05.2025 06.08.2025 06.11.2024 13.03.2025
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+0,00%
8,32 €
ATH 30,00 €
+4,12% +7,67% +103,42% +94,39% -51,06%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL